Business context and reporting period
Issuer identification: The supplied filing is AcelRx Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended June 30, 2023 (ticker ACRX), not a filing identified as Talphera, Inc. The summary below reflects the filing text provided.
AcelRx is a specialty pharmaceutical company focused on therapies for medically supervised settings. Following its April 3, 2023 sale of the DSUVIA/DZUVEO business to Alora, its continuing portfolio centered on Niyad and other nafamostat candidates, plus licensed ephedrine and phenylephrine pre-filled syringe candidates. Financial statements are unaudited; prior-year comparisons were recast to present DSUVIA as discontinued operations.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are in millions unless stated otherwise.
| Metric | Q2 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Royalty revenue | $0.253 | $0.253 |
| Research and development expense | $1.552 | $2.599 |
| Selling, general and administrative expense | $2.670 | $6.951 |
| Operating loss | $(3.969) | $(9.297) |
| Net loss from continuing operations | $(4.428) | $(4.364) |
| Net income (loss) from discontinued operations | $0.057 | $(8.159) |
| Total net income (loss) | $(4.371) | $(12.523) |
| Net loss per share | $(0.40) | $(1.15) |
The $0.253 million royalty was related to DoD sales of DSUVIA under Alora’s marketing arrangement. With revenue at this level, operating margins are not a meaningful indicator of commercial performance.
At June 30, cash and cash equivalents were $7.410 million, down from $15.275 million at year-end 2022. There were no short-term investments or restricted cash reported at June 30. Total assets were $17.725 million, total liabilities $7.306 million, and stockholders’ equity $10.419 million. The Oxford loan was repaid in full on April 3; the company reported no remaining long-term debt at quarter-end.
For the first half, operating cash use was $10.583 million, investing cash provided was $3.123 million, and financing cash use was $5.405 million. Cash, cash equivalents and restricted cash declined by $12.865 million to $7.410 million. Investing cash included $2.723 million of proceeds from the DSUVIA asset sale; financing outflow primarily reflected debt repayment.
Material changes versus the prior comparable period
- Q2 2023 operating loss was $3.969 million versus $9.955 million in Q2 2022; first-half operating loss was $9.297 million versus $14.891 million. The filing attributes lower SG&A mainly to reduced headcount, while R&D increased, primarily from Niyad development.
- R&D increased 42% in Q2 and 35% in the first half year over year; SG&A decreased 33% and 14%, respectively.
- Net income reported in 2022 is not a like-for-like operating comparison: it included an $84.052 million gain from terminating a liability related to a prior royalty monetization. 2023 reported a net loss.
- The DSUVIA business was classified as discontinued operations, and the sale closed in April 2023. AcelRx may receive sales royalties and up to $116.5 million in sales-based milestones, but receipts depend on Alora’s commercialization and sales performance.
- Common shares outstanding were 10,994,102 at June 30, versus 8,243,680 at December 31, 2022. A July 2023 financing issued additional shares and warrants, creating potential further dilution.
Outlook, risks and unusual items
- Going concern and funding: Management stated that current resources and expected spending would require additional capital before the 12-month anniversary of the filing date; the filing says substantial doubt exists about the company’s ability to continue as a going concern. On July 20, after quarter-end, AcelRx closed a private placement with $10.0 million gross proceeds before fees and expenses. Warrants could provide up to a further $16.3 million if exercised, but that amount is not assured. Management said these plans were not entirely within its control and could not be assessed as probable.
- Development outlook: AcelRx submitted an EUA request for Niyad to the FDA on April 27 and stated its aim was to obtain an EUA in 2023, while pursuing a clinical study for full regulatory approval. The filing notes that the EUA request is premised on a significant potential COVID-19 public health emergency; the end of the broader PHE may affect prospects. Niyad’s IDE remained under FDA review. Filing for the ephedrine and phenylephrine product candidates’ NDAs was planned, with Fedsyra filing expected in 2023.
- Commercial and supply risks: DSUVIA royalty and milestone receipts depend on Alora’s sales, including unpredictable DoD orders. AcelRx also cited reliance on third-party suppliers and a single source for nafamostat API; it signed a supply memorandum of understanding, but a longer-term master supply agreement remained to be executed.
- Unusual items: First-half results included a $4.012 million noncash gain from a decrease in warrant liability fair value, a $6.935 million impairment of net assets held for sale, a $1.065 million fixed-asset impairment, and a $1.098 million gain on termination of lease liabilities. Q2 included a $1.299 million increase in warrant liability fair value, contributing to other expense.
- Legal and controls: A securities class action was dismissed in part and without leave to amend in part; the plaintiff had until September 5, 2023 to file a further amended complaint. Related derivative litigation remained stayed. The company said it could not estimate a reasonably possible loss. A prior material weakness involving EPS accounting had led to restatements of 2022 quarterly statements; management said remediation was complete as of June 30, 2023.
- Listing: Nasdaq had notified AcelRx of a minimum-bid-price deficiency in April; the company regained compliance in June. The filing warns that maintaining listing compliance remains a risk.
Important facts for investors to verify
- Confirm the issuer: the provided document names AcelRx Pharmaceuticals, Inc. (ACRX), not Talphera, Inc.
- Review subsequent financing terms, fees, registration obligations, warrant exercise conditions and dilution; distinguish the $10.0 million received from potential warrant proceeds.
- Assess cash runway and financing needs in light of the explicit going-concern uncertainty and continuing operating cash burn.
- Track FDA decisions and milestones for Niyad, including EUA and IDE status, the clinical path to PMA, and the impact of the COVID-19 EUA basis.
- Monitor DSUVIA sales, DoD ordering patterns, Alora’s commercialization, and the resulting royalties and milestone eligibility.
- Check progress toward a binding nafamostat supply agreement and readiness of the pre-filled syringe NDA submissions.
- Review the securities and derivative litigation developments and confirm ongoing effectiveness of the remediated EPS controls.